Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.44 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL882530 | 0.90 | TMPRSS2 (0.41) | TMPRSS2ACVRL1PIK3CD | |
| SCHEMBL24606306 | 0.86 | TMPRSS2 (0.41) | TMPRSS2POLRMTPIK3CD | |
| SCHEMBL10120049 | 0.85 | TMPRSS2 (0.38) | TMPRSS2 | |
| SCHEMBL23822916 | 0.85 | TMPRSS2 (0.48) | TMPRSS2 | |
| SCHEMBL20078677 | 0.85 | TMPRSS2 (0.40) | TMPRSS2POLRMTPIK3CD | |
| SCHEMBL13667660 | 0.84 | TMPRSS2 (0.41) | TMPRSS2POLRMT | |
| SCHEMBL23034569 | 0.83 | TMPRSS2 (0.36) | TMPRSS2POLRMT | |
| SCHEMBL18636432 | 0.83 | TMPRSS2 (0.36) | TMPRSS2POLRMT | |
| SCHEMBL19504314 | 0.83 | TMPRSS2 (0.38) | TMPRSS2 | |
| SCHEMBL24789693 | 0.83 | POLRMT (0.38) | TMPRSS2POLRMTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | STARPHARMA PTY LTD (AU) | 2023-08-24 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-2595980-B1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2014-09-03 | — | — | EP | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | TMPRSS2 3100/4885POLRMT 49/4885ACVRL1 4753/4885 |
| US-20150111839-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885POLRMT 148/4885ACVRL1 3874/4885 |
| US-20150152116-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885POLRMT 148/4885ACVRL1 3874/4885 |
| US-11382926-B2 | Methods for treating Arenaviridae and Coronaviridae virus infections | ACE, PNP, ACE2 | TMPRSS2 12/4885POLRMT 1645/4885ACVRL1 4649/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TMPRSS2 433/4885POLRMT 148/4885ACVRL1 3874/4885 |
| US-20230263900-A1 | DENDRIMER-DRUG CONJUGATE | SARS1, MMAB, PAM | TMPRSS2 68/4885POLRMT 454/4885ACVRL1 3316/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | TMPRSS2 6/4885POLRMT 450/4885ACVRL1 4804/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | TMPRSS2 12/4885POLRMT 1645/4885ACVRL1 4649/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TMPRSS2 6/4885POLRMT 450/4885ACVRL1 4804/4885 |
| US-20230027727-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | PNP, ACE, ACE2 | TMPRSS2 14/4885POLRMT 1679/4885ACVRL1 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.